Vasopressin in chronic kidney disease: an elephant in the room?
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 19829311.
- Also identified by DOI 10.1038/ki.2009.325 and PMC identifier 2925670.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Perico et al. report that a dual arginine vasopressin (AVP) V(2) and V(1a) receptor antagonist lowers blood pressure, proteinuria, and glomerulosclerosis in 5/6 nephrectomized rats, pointing to its potential value in the treatment of chronic kidney disease (CKD). AVP likely contributes to CKD progression by its effects on renal hemodynamics, blood pressure, and mesangial and/or epithelial cells, but the relative contributions of V(2) and V(1a) receptors and potential usefulness of V(2) and V(1a) receptor antagonists remain ill defined.
Medical subject headings
- Arginine Vasopressin
- Kidney
- Kidney Diseases
- Receptors, Vasopressin